Streetbeat News

Stock Prices

AMAT

AMD

Applied Materials (AMAT) stock is up 5.3% to $207.23, driven by strong earnings from Advanced Micro Devices (AMD) and potential exemptions from new export restrictions on chip equipment to China. This suggests increased demand for AMAT's semiconductor manufacturing equipment.

Portfolio Pulse from Henry Khederian

July 31, 2024 | 3:11 pm

QRVO

Qorvo shares are trading lower following the company's Q1 financial results.

Portfolio Pulse from Benzinga Newsdesk

July 31, 2024 | 3:08 pm

FFIE

Faraday Future Intelligent Electric Inc. (NASDAQ:FFIE) shares are trading higher after the company provided a business update and regained compliance with Nasdaq reporting requirements. The company reported a significant reduction in losses and operating expenses for Q1 2024 compared to the same period last year. The new China-U.S. Automotive Bridge Strategy and recent fundraising efforts are expected to drive future growth.

Portfolio Pulse from Erica Kollmann

July 31, 2024 | 3:07 pm

INJUSD

Injective (CRYPTO: INJ) has seen a price decrease of 3.16% in the past 24 hours, continuing a week-long downward trend of 9.0%. Trading volume has decreased by 4.0%, and the circulating supply has slightly decreased by 0.11%. The current market cap ranking for INJ is #46 at $2.24 billion.

Portfolio Pulse from Benzinga Insights

July 31, 2024 | 3:02 pm

NRIX

Over the past three months, 13 analysts have evaluated Nurix Therapeutics (NASDAQ:NRIX), with a mix of bullish and somewhat bullish ratings. The average 12-month price target has increased to $29.54, reflecting a 6.64% rise from the previous target. Analysts have adjusted their ratings and price targets, with notable actions including Truist Securities announcing a 'Buy' rating with a $36.00 target and JP Morgan raising its target to $34.00. Despite revenue challenges and below-average ROE and ROA, Nurix maintains a balanced debt approach.

Portfolio Pulse from Benzinga Insights

July 31, 2024 | 3:01 pm

NMIH

NMI Holdings (NASDAQ:NMIH) has received a range of analyst ratings over the past quarter, with a mix of bullish, somewhat bullish, and indifferent views. Analysts have set a 12-month price target averaging $40.5, reflecting an 11.97% increase from the previous average. Recent ratings adjustments by analysts from firms like RBC Capital, Truist Securities, Barclays, JP Morgan, UBS, and Compass Point indicate a positive outlook for the company.

Portfolio Pulse from Benzinga Insights

July 31, 2024 | 3:01 pm

NXRT

Four analysts have provided mixed ratings for NexPoint Residential (NYSE:NXRT) over the past quarter, with one bullish rating and three indifferent ratings. The average 12-month price target has increased by 7.89% to $41.0. Key analysts have adjusted their ratings and price targets, reflecting their responses to market conditions and company performance.

Portfolio Pulse from Benzinga Insights

July 31, 2024 | 3:01 pm

COIN

The article provides a detailed comparison of Coinbase Global Inc. (NASDAQ: COIN) with its competitors in the Capital Markets industry. It highlights Coinbase's high valuation ratios (P/E, P/B, P/S) and strong operational metrics (ROE, EBITDA, gross profit, revenue growth) relative to industry averages. The analysis suggests potential overvaluation but also underscores Coinbase's robust financial performance and growth prospects.

Portfolio Pulse from Benzinga Insights

July 31, 2024 | 3:00 pm

AN

AutoNation, Inc. (NYSE:AN) reported Q2 earnings that missed analyst expectations due to a cyber incident at CDK Global. Despite the miss, the company showed strong cash flow and capital allocation, including significant share repurchases. AN shares rose 6.78% following the report.

Portfolio Pulse from Nabaparna Bhattacharya

July 31, 2024 | 3:00 pm

MRK

The article provides a comprehensive comparison of Merck & Co (NYSE:MRK) against its competitors in the Pharmaceuticals industry, focusing on key financial metrics, market position, and growth prospects. Merck shows potential undervaluation with low PE, PB, and PS ratios, and strong profitability with a high ROE. However, it faces challenges with lower EBITDA, gross profit, and revenue growth compared to industry averages.

Portfolio Pulse from Benzinga Insights

July 31, 2024 | 3:00 pm